EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase I)

A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone ( BrEPEM ) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial

Cecilia Carpio iD, Fátima de la Cruz-Vicente, Ramon García-Sanz, Izaskun Zeberio, Cristina Barrenetxea, Eva Domingo-Domenech, Mariana Bastos iD, Araceli Rubio Martinez, Pilar Gómez-Prieto, Antonia Rodriguez, Maria Casanova, Antonia Cladera-Serra und 6 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Cecilia Carpio und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hodgkin Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Takeda Pharmaceuticals International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classical Hodgkin lymphoma (cHL) has high curability following initial standard treatments. A less favourable outcome is observed in patients aged ≥60 (poorer tolerability and efficacy). Low‐intensity chemotherapies are currently employed for this group of patients, although there is still a need for improvement. This phase Ib/II multicentre, single‐arm study evaluated the safety and efficacy of the combination of brentuximab vedotin with cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone (BrEPEM) in older untreated patients with cHL. Forty patients were enrolled (6 phase Ib; 34 phase II). Median age was 73 years (range: 67–88), 93% stage III/IV and median Cumulative Illness Rating Scale–Geriatric (CIRS‐G) was 5 (range: 1–28). The median follow‐up was 43.2 months. The most common adverse events were haematological toxicities (neutropenia G ≥3: 32%). During treatment, five patients died from infections. Per protocol /intention‐to‐treat analysis showed an overall response of 93%/63% and a complete response of 89%/60% respectively. Median progression‐free survival (PFS) and overall survival (OS) were 14.3 months (95% confidence interval [CI] = 11.5–not reached [NR]) and NR (95% CI = 29.5–NR) respectively. Estimated 2‐year PFS and OS were 44% (95% CI = 31–62) and 69% (95% CI = 56–85) respectively. BrEPEM is an alternative option for older untreated cHL patients, albeit not exempt from toxicity. Studies directed to better patient selection are needed to improve survival and mitigate toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHodgkin DiseaseHumansAgedBrentuximab VedotinMaleFemaleCyclophosphamideEtoposideProcarbazineAged, 80 and overMitoxantronePrednisone

Stichwörter der Autor:innen

Hodgkin's lymphomabrentuximab vedotinfirst lineoldertreatment

Substanzen

Brentuximab VedotinCyclophosphamideEtoposideProcarbazineMitoxantronePrednisone

Autor:innen und Institutionen

  • Department of Haematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
  • Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Department of Haematology, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Department of Haematology, Hospital Universitario de Salamanca (HUS/Instituto de Investigacion Biomedica de Salamanca), CIBERONC and Center for Cancer Research-Instituto de Biología Molecular y Celular del Cáncer (Unive…
  • Department of Haematology, Hospital Universitario de Donostia, San Sebastián, Spain.
  • Department of Haematology, Hospital Universitario Basurto, Bilbao, Spain.

ORCID-Profile: Cecilia Carpio, Mariana Bastos, Carmen Martínez

Förderung

  • Takeda Pharmaceuticals International

Zitieren

APA

Carpio, C., de la Cruz-Vicente, F., García-Sanz, R., Zeberio, I., Barrenetxea, C., Domingo-Domenech, E., Bastos, M., Rubio Martinez, A., Gómez-Prieto, P., Rodriguez, A., Casanova, M., Cladera-Serra, A., Nuñez Cespedes, J., Martínez, C., Moreno-Velázquez, M., Garcia-Galea, E., Abrisqueta, P., & Bosch, F. (2025). A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone ( BrEPEM ) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial. British Journal of Haematology. https://doi.org/10.1111/bjh.70028

Vancouver

Carpio C, de la Cruz-Vicente F, García-Sanz R, Zeberio I, Barrenetxea C, Domingo-Domenech E, et al. A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone ( BrEPEM ) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial. British Journal of Haematology. 2025. doi:10.1111/bjh.70028

BibTeX
@article{Carpio2025,
  author = {Carpio, Cecilia and de la Cruz-Vicente, Fátima and García-Sanz, Ramon and Zeberio, Izaskun and Barrenetxea, Cristina and Domingo-Domenech, Eva and Bastos, Mariana and Rubio Martinez, Araceli and Gómez-Prieto, Pilar and Rodriguez, Antonia and Casanova, Maria and Cladera-Serra, Antonia and Nuñez Cespedes, Javier and Martínez, Carmen and Moreno-Velázquez, Miriam and Garcia-Galea, Eduardo and Abrisqueta, Pau and Bosch, Francesc},
  title = {A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone ( BrEPEM ) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70028}
}
Kostenlos starten →